The present invention relates to subtilisin variants and methods for obtaining subtilisin variants.
When the protease is subtilisin, the protease inhibitor is preferably a modified subtilisin inhibitor of Family VI.
The invention relates to subtilisin enzymes which have been modified by mutating a nucleotide sequence (gene) coding for the subtilisin.
Subtilisin: colorimetric method based on the quantification of water soluble dyed fragments (azurine) produced by the action of subtilisin on commercially available cross-linked casein substances.
The modified subtilisin enzymes have enhanced thermal stability.
The present invention provides a Bacillus sp. subtilisin variant.
In the case of PrioCHECK Trichinella AAD, this enzyme is a subtilisin.
Debridement activity of enzymes such as subtilisin A, subtilisin, bromelain and the like is enhanced when combined with one or more antibiotics.
In some embodiments, the medicament includes subtilisin.
Crystalline subtilisin is produced by adding a halide salt, such as sodium chloride or calcium chloride, to a concentrated subtilisin solution (at least about 40 g/l).
Structure of a switchable subtilisin complexed with a substrate and with the activator azide.
In accordance with the present invention, novel methods and compositions including the enzyme subtilisin A or including the combination of an enzyme such as subtilisin A and one or more pharmaceutical agents, e.g. antibiotics, are disclosed.
The present invention provides a subtilisin variant that is particularly well suited to cleaning applications.
The present invention also relates to DNA sequences encoding such Subtilisin DY variants.
Antagonists of human proprotein convertase subtilisin-kexin type 9 ("PCSK9") are disclosed.
The present invention relates to variants of Streptomyces subtilisin inhibitor (SSI) and those inhibitors having homology to SSI.
Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed.
In particular, the present invention provides a Bacillus sp. subtilisin variant and cleaning compositions comprising this variant.
In a particular embodiment the serine protease is a subtilisin.
PCSK-9 (properdin convertase subtilisin/kexin-9) was discovered in 2003.
Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed.
The subtilisin variants are therefore useful additives in cleaning compositions.
Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed.
Antagonists of human proprotein convertase subtilisin-kexin type 9 ("PCSK9") are disclosed.
The invention relates to novel alkaline protease variants, which are derived from natural or modified subtilisin proteases.
Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed.
Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed.
This process does not produce amorphous subtilisin even at high salt concentrations in the solution.
The present disclosure relates to subtilisin protease conjugate comprising a protease moiety and one or more addition moieties.
Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed.
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод